CAI
Caris Life Sciences, Inc.
There isn't enough reported data to score CAI yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CAI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Strong |
CAI's revenue and balance sheet are currently healthy, and its profitability and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CAI PE Valuation
CAI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CAI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for CAI, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CAI Earnings Per Share
CAI and OSCR do not have enough comparable growth data to identify a winner.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CAI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $275.4M | +27% |
| Q2 2026 | $263.7M | +45% |
| Q1 2026 | $216.2M | +79% |
| Q4 2025 | $292.9M | +125% |
| Q3 2025 | $216.8M | +113% |
| Q2 2025 | $181.4M | +81% |
| Q1 2025 | $120.9M | +50% |
| Q3 2021 | $100.8M | +28% |
CAI has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -8 points |
| Q2 2026 | 10% | +20 points |
| Q1 2026 | 2.4% | +50 points |
| Q4 2025 | 30% | +59 points |
| Q3 2025 | 15% | +75 points |
| Q2 2025 | -9.9% | -77 points |
| Q1 2025 | -48% | +66 points |
| Q4 2024 | -29% | -94 points |
CAI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.7M | -172% |
| Q1 2026 | $22.5M | +$56.6M |
| Q4 2025 | $39.7M | +$80.9M |
| Q3 2025 | $55.3M | +$126.6M |
| Q1 2025 | -$34M | +$41.6M |
| Q3 2021 | -$447.6M | -895% |
| Q2 2021 | -$18.8M | -131% |
| Q1 2021 | -$95.9M | -397% |
CAI's free cash flow has turned positive after three years mostly in the red: $29M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CAI on cash generation, producing positive trailing cash flow while its opponent burns cash.
CAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.3% | +12.3M shares |
| 1 year | +355% | +230M shares |
CAI has 295M diluted shares, up 355% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10M |
| Q2 2026 | $21.4M |
| Q1 2026 | — |
| Q4 2025 | $91,000 |
| Q3 2025 | — |
| Q1 2025 | $22,000 |
| Q4 2024 | — |
| Q3 2024 | — |
CAI spent $31M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CAI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CAI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -3.4x | Net Cash |
| Q4 2025 | -11.6x | Net Cash |
| Q3 2021 | 7.5x | High |
| Q2 2021 | 6.5x | High |
| Q1 2021 | 6.2x | High |
| Q4 2020 | 6.7x | High |
| Q3 2020 | 9.6x | High |
| Q2 2020 | 8.5x | High |
CAI has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 51.8 | Neutral |
CAI's weekly RSI is 48 (neutral) and its Stochastic is 52 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CAI PE vs Healthcare Sector
CAI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.5 | 19% below |
| 20 week MA | $24.7 | 3.2% below |
| 50 week MA | $22.5 | 6.7% above |
OSCR has stronger trend alignment. CAI is above 1 of 3 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $27.3 | $28.2 | +3.6% |
| 2026 YTD | $28.2 | $24.0 | -15% |
CAI has finished every year since 2025 higher, and it's down 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CAI on returns for 2026, with the stronger performance.